Jyong Biotech (MENS) Total Non-Current Liabilities (2024 - 2025)
Jyong Biotech (MENS) posted quarterly Total Non-Current Liabilities of $10.9 million for Q4 2025, down 64.65% year-over-year from $30.8 million in Q4 2024, and down 66.63% quarter-over-quarter from $32.6 million in Q2 2025.
Jyong Biotech (MENS) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Jyong Biotech's Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $10.9 million for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 64.65% year-over-year to $10.9 million; the TTM figure through Dec 2025 stood at $10.9 million (down 64.65% YoY), while the FY2025 annual figure was $10.9 million, down 64.65% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $10.9 million, down from $32.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $32.6 million in Q2 2025, with the low at $10.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Jyong Biotech | 159.89 Mn | 159.89 Mn | - | 10.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.87 Mn |
| Jun 30, 2025 | 32.59 Mn |
| Dec 31, 2024 | 30.76 Mn |